CMC Detection via Multi-Biomarker Panel and Morphology
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting circulating melanoma cells (CMCs) in blood samples face challenges due to low recovery rates and limited biomarkers, making it difficult to accurately diagnose metastatic melanoma.
Innovation Solution
A method involving non-enriched blood samples, where detectable agents specific for CMC biomarkers such as CSPG4, Pmel17, or S100A1 are used in combination with morphological assessments to identify CMCs, utilizing immunofluorescent markers and automated microscopy for accurate detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If immunomagnetic enrichment of tumor cells is used, then CMC detection sensitivity is improved, but only CMCs with sufficient expression of selected surface markers are detected, limiting detection coverage
Solution Approach 1:
The patent uses a panel of multiple detectable agents targeting different CMC biomarkers (CSPG4, Pmel17, S100A1) simultaneously, allowing the detection system to identify CMCs with diverse marker expressions. This multi-functional approach ensures comprehensive detection coverage across different CMC populations while maintaining high sensitivity through automated microscopy analysis.
2Measurement precision
If negative selection with anti-CD45-coated immunomagnetic beads is used, then peripheral blood mononuclear cells are removed, but CMC detection still faces limitations due to low recovery rates
Solution Approach 1:
The patent replaces mechanical immunomagnetic enrichment methods with an automated microscopy-based detection system. Non-enriched blood samples are directly analyzed using automated imaging and machine learning algorithms to identify CMCs based on morphological and immunophenotypic characteristics. This substitution eliminates recovery rate limitations inherent in magnetic separation methods while maintaining high detection accuracy.
3Ease of operation
If physical differences between PBMCs and CMCs such as size or density are used for enrichment, then separation is achieved, but technical inadequacies result in low recovery rates
Solution Approach 1:
The patent changes the detection parameters from physical properties (size, density) to molecular and morphological parameters. By using detectable agents that bind to specific CMC biomarkers and automated microscopy that analyzes cellular morphology, the system achieves accurate CMC identification without relying on physical enrichment methods that suffer from low recovery rates.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables sensitive and specific detection of CMCs, even at low concentrations, facilitating timely diagnosis and treatment of metastatic melanoma with high classification sensitivity.
Implementation Method 1
contacting a biological sample of non-enriched blood with one or more detectable agents, wherein at least one of said one or more detectable agents is specific for a biomarker of CMCs
Implementation Method 2
In one embodiment, said one or more detectable agents comprise a immunofluorescent marker
Data Source
Figure 1A~1B
Figure 2A~2C
Figure 3
AI summary
The present invention provides methods for identifying circulating melanoma cells (CMCs) in a biological sample and methods for diagnosing metastatic melanoma in a subject. The methods disclosed can be used on non-enriched blood samples to identify CMC using detectable agents that are specific for a biomarker of CMCs and assessing the morphology of the cells having the detectable agents. The presence or absence of a detectable agent in combination with morphological characteristics of the cells can be used diagnose a subject with metastatic melanoma based on the number of CMCs is present in the sample.